TIM-3 blockade enhances ex vivo stimulated allogeneic NK cell therapy for relapsed murine neuroblastoma after hematopoietic cell transplant
Aicha E. Quamine, Evan L. Dray, Nicholas R Mohrdieck, Chloe A King, Anastasia A Griggs, Jillian M Kline, Monica M. Cho, S. P. Rinella, Katharine E. Tippins, Paul D. Bates, Lei Shi, Longzhen Song, Nicholas J Hess, Tyce J. Kearl, Bryon D. Johnson, Christian M. Capitini
This study shows that combining TIM-3 blockade with ex vivo stimulated allogeneic NK cells improves survival and reduces tumor growth in a murine neuroblastoma model after allo-HCT without increasing GVHD.
Journal for ImmunoTherapy of Cancer · Dec 1, 2025Peer-reviewedImmunology